期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 64, 期 21, 页码 16132-16146出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.1c01441
关键词
-
资金
- National Natural Science Foundation of China [21778028, 22077055, 82003779]
- Macao Young Scholars Program [AM201926]
- Natural Science Foundation of Gansu Province [20JR5RA311, 18JR4RA003]
- 111 project
The study prepared different amino-substituted phenylarsine oxides and found that the o-substituted molecule exhibited higher potency in inhibiting cellular TrxR activity, leading to oxidative stress-mediated apoptosis. These findings suggest the promising potential of TrxR inhibitors as cancer therapeutic agents.
Upregulation of the selenoprotein thioredoxin reductase (TrxR) is of pathological significance in maintaining tumor phenotypes. Thus, TrxR inhibitors are promising cancer therapeutic agents. We prepared different amino-substituted phenylarsine oxides and evaluated their cytotoxicity and inhibition of TrxR. Compared with our reported p-substituted molecule (8), the o-substituted molecule (10) shows improved efficacy (nearly a fourfold increase) to kill leukemia HL-60 cells. Although the compounds 8 and 10 display similar potency to inhibit the purified TrxR, the o-substitution 10 exhibits higher potency than the p-substitution 8 to inhibit the cellular TrxR activity. Molecular docking results demonstrate the favorable weak interactions of the o-amino group with the TrxR C-terminal active site. Efficient inhibition of TrxR consequently induces the oxidative stress-mediated apoptosis of cancer cells. Silence of the TrxR expression sensitizes the cells to the arsenic compound treatment, further supporting the critical involvement of TrxR in the cellular actions of compound 10.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据